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ADD cut-point was based on the ineffectiveness of DF in reducing the number of 
new brain lesions at doses < 360 mg/day.1 Results: The study sample consisted of 
2,879 patients; 19.8% relapsed within 9 months, with an average time to relapse of 
110 days (standard deviation: 77.9). A higher proportion of non-adherent patients 
relapsed versus adherent patients (23.4% vs. 17.9%; p= 0.0004). A higher propor-
tion of patients with suboptimal ADD experienced relapse compared with those 
with ADD ≥ 360 mg/day (26.7% vs. 17.9%, p< 0.0001). Non-persistence was associ-
ated with a higher occurrence of relapse compared with persistence (25.0% vs. 
18.2%, p= 0.0001). ConClusions: Non-adherence and suboptimal dosing with DF 
were related to higher relapse rates in MS patients in a real-world setting. Further 
research is needed to confirm these findings for other DMTs and to quantify the 
level of non-adherence with its impact on effectiveness.REFERENCES: 1. Kappos 
L, et al. Lancet. 2008;372:1463-72. 2. Chastek BJ, et al. J Med Econ. 2010;13:618-25.
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objeCtives: Multiple sclerosis (MS) is an acquired chronic immune-mediated 
inflammatory condition of the central nervous system. It is the commonest cause 
of serious physical disability in adults of working age. Inequalities in access to 
treatment and care for MS have been recognised within the UK and when the UK 
is compared with Europe eg. 69% of patients in Germany have access to disease 
modifying therapies versus 21% of patients in the UK. Recent NICE guidance has 
been issued to tackle the inequalities in access to care for MS in England, however 
uptake of NICE Guidance is not uniform across the country, leading to delays and 
restrictions in access to treatment for patients in some areas. This paper aims to 
assess the current variation in access to treatment for MS in England. Methods: 
Prescribing of fingolimod for MS in England was examined using the NHS England 
Innovation Scorecard for Key Secondary Care Medicines per 100,000 population. 
Uptake of fingolimod across the 25 area teams was examined. Results: Despite 
positive NICE guidance for fingolimod issued in April 2012 there are major differ-
ences in the uptake of fingolimod in England. The highest uptake can be seen in 
the London area and in other area team geographies in the south. Uptake in these 
areas is at least 3 fold and in some cases 7 fold greater than that seen in area team 
geographies in the North West. Some of this variation may be explained by proximity 
to specialist care centres, however the existence of these centres does not explain 
the extent of the variation. ConClusions: Variations in access to treatment for 
MS in England persist despite NICE guidance and NHS reform aimed at addressing 
these inequalities.
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objeCtives: Multiple Sclerosis (MS) is a progressive and debilitating condition with 
long-term impacts on patients and healthcare resources. Natalizumab is a disease-
modifying biologic used in MS and administered by intravenous infusion every 28 
days. This analysis evaluated the impact of natalizumab on hospital activity using 
Hospital Episodes Statistics (HES) data. Methods: A retrospective analysis of HES 
was performed using data for the specific period January 2010 to May 2012 (29 
consecutive months). Data after May 2012 was not used due to the introduction of 
a second drug which could not be differentiated from natalizumab. A systematic 
HES coding search identified patients via ICD and OPCS codes and patterns of hos-
pital attendance. Attendances were collated for the period from 6 months pre- and 
6 months post- natalizumab initiation. Healthcare utilisation metrics included: 
number of planned & unplanned hospital visits, planned & unplanned bed days, 
and outpatient appointments. Results: Comparing pre- with post- natalizumab 
periods there was a 50.0% reduction in mean unplanned hospital visits per patient (p 
= 0.010) and a 49.6% reduction in the mean number of bed days per unplanned visit 
(p = 0.027). Other observations included a 74.8% reduction in the mean number of 
unplanned bed days per patient (p = 0.138) and a 44.8% increase in mean outpatient 
appointments per patient (p = 0.351) however these were not statistically significant. 
As expected, natalizumab was associated with an increase in planned admissions 
although the mean number of bed days per planned admission was reduced by 
87.0% (p = 0.004). The changes to in-patient admissions were estimated to deliver a 
small reduction in healthcare expenditure. ConClusions: The pattern of changes 
in hospital activity associated with natalizumab support the expected positive clini-
cal outcomes. Confounding aspects were an identification bias in the non-random 
sampling and the potential for a regression to the mean effect.
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objeCtives: There is currently no cure for Duchenne muscular dystrophy (DMD), 
which results in progressive paralysis and death generally in early adulthood. 
Available treatments only address symptoms, with limited success. However, sev-
eral new therapies targeting underlying genetic components of the disease have 
passed pre-clinical phases of drug development. In anticipation of new therapies 
coming to market, we sought to examine current treatment patterns, resource 
1b, Peginterferon beta-1a, Teriflunomide, Dimethyl Fumarate and Azathioprine, 
detected by ATC Code. We extrapolated results to whole SHI by adjusting for dif-
ferences in demographics of insured between TK and SHI. Results: G-BA issued 
additional benefit of Fingolimod only for patients with rapidly evolving severe RRMS, 
i.e. 1.500 patients in Germany. We observed 9.538 patients with MS and prescrip-
tion of Fingolimod in SHI in 2013 and 11.085 in 2014, corresponding to about every 
10th patient with MS and prescription of DMT. Total outpatient pharmaceutical 
expenditure for DMT was million € 1,843 in 2014, million € 210 (11.4%) caused by 
Fingolimod. ConClusions: HTA and drug safety warnings don´t seem to influence 
prescribing behaviour. This might be accompanied by additional costs for SHI and 
doubtful benefit for patients. Whether marketing or patient demand is responsible 
for over-prescription needs to be discussed elsewhere.
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objeCtives: Fingolimod oral capsules were the first oral disease modifying agent 
(DMT) approved in the United States (US) in September 2010 for the treatment of 
relapsing remitting multiple sclerosis (RRMS). The objective of this study is to assess 
the characteristics of RRMS patients taking Fingolimod capsules in the US. Methods: 
A large US administrative retrospective claims database was used to identify patients 
diagnosed with RRMS and were prescribed Fingolimod between January 2010 to 
December 2012 were included in the study. All patients were ≥ 18 years of age and 
continuously enrolled in the same health plan for a year. Descriptive statistics and 
chi-square tests were performed on the data and statistical significance level was 
set a priori at 0.05. Results: There were a total of 28,447 patients that met the study 
inclusion criteria. Of these, 21,629 (75.9%) were females, mean age was 49.1±10.0 
years, and males were older than females (49.78 vs 48.9 years; P< 0.001) with a sta-
tistical significance different between them. Thirty four percentage of the patients 
were from Midwest, 25.5% were from East, 34.4% from south and 5.2% from West of 
the USA. Thirty three percentage of the patient’s prescription was with their health 
plan formulary and received an average of supply of 31.6 ± 13.6 days. Majority (60.9%) 
of the patients was under group coverage and 59.1% of patients were diagnosed 
with having mental health problems. Females enrolled continuously (5.1 ± 2.4 vs 
5.0 ± 2.4 years) much longer than males in the same health plan. But, females had a 
higher number of total claims (488.2 ± 389.0 vs 416.6 ± 389.0) during the enrollment 
period. ConClusions: Majority of the patients taking Fingolimod was females and 
had more number of claims related to MS than males. And, majority of the patients 
were dispensed Fingolimod for only one month supply.
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objeCtives: The objective of this study is to assess the characteristics of relapsing 
remitting multiple sclerosis patients taking disease modifying therapies (DMTs) in 
the US. Methods: A large US administrative retrospective claims database was 
used to identify patients diagnosed with Multiple Sclerosis (MS) and were pre-
scribed DMTs between January 2010 to December 2012 were included in the study. 
All patients were ≥ 18 years of age and continuously enrolled in the same health 
plan for a year. Descriptive statistics and chi-square tests were performed on the 
data and statistical significance level was set a priori at 0.05. Results: There were 
a total of 741,065 patients that met the study inclusion criteria. The mean age of the 
patients was 52.38 ± 10.50 years, 75.7% of the patients were females, and majority 
of the patients were between 41 to 64 years of age (73.5%). Thirty two percent of 
the patients were from East, 34.6% were from Midwest, 25% from South and 7.8% is 
from West region. 56.6% of the patients were on a group coverage plan and 62.6% of 
the patients were on a DMT prescription that is under their health plan formulary. 
Majority of the patients (92.9%) were prescribed 30 days’ supply of DMTs, 6.3% 
were on 90 days’ supply and only 0.8% were on 60 days’ supply of DMTs. More 
than half of the patients (55.7%) were diagnosed with mental health problems in 
addition to their RRMS as a primary diagnosis. On average, patients were continu-
ously enrolled for 5.36 ± 2.40 years and submitting around 446 claims during this 
period. ConClusions: The majority of the patients was females and was between 
41 to 64 years of age. And majority of the patients received 30 days’ supply of DMTs.
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objeCtives: To explore the relationship between medication-use patterns of mul-
tiple sclerosis (MS) disease-modifying therapy (DMT) and relapse in a real-world 
setting. Methods: This was a retrospective, observational study using administra-
tive claims data. Dimethyl fumarate (DF), a DMT, was selected for analysis due to 
availability of medication-dosing data in relation to efficacy observed in a clinical 
trial.1 Adult MS patients with DF claims (March 2013–January 2014) continuously 
enrolled for 9 months before and after therapy initiation were included. A validated 
algorithm was used to define relapse by either an inpatient claim with a primary 
MS diagnosis or a systemic corticosteroid claim within 7 days of an MS outpa-
tient visit.2 Medication-use patterns were assessed by non-adherence (medica-
tion possession ratio (MPR) < 0.90), suboptimal average daily dose (ADD < 360 mg/
day), and treatment non-persistence (DMT switch or ≥ 30-day gap in therapy). The 
